Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

BDSX - Biodesix, Inc. So'nggi Yangiliklar | Finranks

Home

/

BDSX

B

Biodesix, Inc. (BDSX)

NGM – Real vaqt narxi. Valyuta: USD

24.76

+0.45 (1.85%)

Bozor ochiq: Aug 12, 2026, 11:16 AM EDT

24.33

+0.02 (0.08%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue?

Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue?

Biodesix (BDSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Wall Street Analysts Think Biodesix (BDSX) Could Surge 31.91%: Read This Before Placing a Bet

Wall Street Analysts Think Biodesix (BDSX) Could Surge 31.91%: Read This Before Placing a Bet

The consensus price target hints at a 31.9% upside potential for Biodesix (BDSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Biodesix, Inc. (BDSX) Q2 2026 Earnings Call Transcript

Biodesix, Inc. (BDSX) Q2 2026 Earnings Call Transcript

Biodesix, Inc. (BDSX) Q2 2026 Earnings Call Transcript

Biodesix Q2 Earnings Call Highlights

Biodesix Q2 Earnings Call Highlights

Biodesix NASDAQ: BDSX reported second-quarter 2026 revenue growth of 34% year over year, supported by increased diagnostic test volumes, higher average revenue per test and continued expansion of its commercial organization.

Biodesix, Inc. (BDSX) Reports Q2 Loss, Beats Revenue Estimates

Biodesix, Inc. (BDSX) Reports Q2 Loss, Beats Revenue Estimates

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $1.6 per share a year ago.

Biodesix to Participate in Canaccord Genuity's 46th Annual Growth Conference

Biodesix to Participate in Canaccord Genuity's 46th Annual Growth Conference

LOUISVILLE, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in a fireside chat and host in-person 1x1 investor meetings at Canaccord Genuity's 46th Annual Growth Conference, which will be held from August 11-12, 2026.

Videolar

No Data

There is no data to display

Press-relizlar

Biodesix to Participate in Canaccord Genuity's 46th Annual Growth Conference

Biodesix to Participate in Canaccord Genuity's 46th Annual Growth Conference

LOUISVILLE, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in a fireside chat and host in-person 1x1 investor meetings at Canaccord Genuity's 46th Annual Growth Conference, which will be held from August 11-12, 2026.